Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Trial: RD 799.35751 (ETH47-101)

Next Previous
X
Search
Trial Profile

Phase 1 Trial: RD 799.35751 (ETH47-101)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ETH-47 (Primary) ; ETH-47 (Primary)
  • Indications Respiratory tract infections
  • Focus Adverse reactions; First in man
  • Acronyms ETH47-101
  • Sponsors ethris

    • Most Recent Events

    • 30 Jan 2025 According to Ethris media release, Based on the encouraging Phase 1 results, Ethris filed a Clinical Trial Application (CTA) for a Phase 2a rhinovirus challenge study in asthma patients, planned to begin in Q2 2025.
    • 30 Jan 2025 According to Ethris media release,company announced promising topline data from this trial at the mRNA-Based Therapeutics Summit Europe in Frankfurt, Germany.
    • 18 Jun 2024 According to Ethris media release, full data readout is planned for the third quarter of 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top